Autolus Therapeutics (AUTL) Gross Margin (2024 - 2025)
Autolus Therapeutics posted quarterly Gross Margin of 4.29% for Q4 2025, up 3916123.0% year-on-year from N/an in Q4 2024, and up 87.81% on a QoQ basis from 35.15% in Q3 2025.
Autolus Therapeutics (AUTL) has 2 years of Gross Margin data on file, last reported at 4.29% in Q4 2025.
- For the quarter ending Q4 2025, Gross Margin rose 3916123.0% year-over-year to 4.29%; the trailing twelve-month figure through Dec 2025 stood at 27.83% (down 1541.0% YoY), and the FY2025 full-year result was 27.83%, down 1531.0% from the prior year.
- Gross Margin for Q4 2025 stood at 4.29%, up from 35.15% in the prior quarter.
- Across five years, Gross Margin topped out at 100.0% in Q1 2024 and bottomed at 39165.52% in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 79.04% |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 86.85% |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 91.79% |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 82.22% |
| 10 | Autolus Therapeutics | - | - | -1.04 Mn | -4.29% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -4.29% |
| Sep 30, 2025 | -35.15% |
| Jun 30, 2025 | -16.83% |
| Mar 31, 2025 | -99.86% |
| Dec 31, 2024 | -39,165.52% |
| Mar 31, 2024 | 100.00% |